Legal & General Group Plc reduced its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1.0% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 54,559 shares of the biopharmaceutical company’s stock after selling 548 shares during the period. Legal & General Group Plc’s holdings in Amicus Therapeutics were worth $390,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Principal Financial Group Inc. boosted its position in Amicus Therapeutics by 1.8% in the first quarter. Principal Financial Group Inc. now owns 26,883 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 487 shares during the last quarter. Creative Planning boosted its stake in shares of Amicus Therapeutics by 56.2% in the first quarter. Creative Planning now owns 16,400 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 5,900 shares during the last quarter. Teachers Advisors LLC boosted its stake in shares of Amicus Therapeutics by 5.4% in the first quarter. Teachers Advisors LLC now owns 253,499 shares of the biopharmaceutical company’s stock worth $1,807,000 after buying an additional 12,936 shares during the last quarter. American International Group Inc. boosted its stake in shares of Amicus Therapeutics by 17.7% in the first quarter. American International Group Inc. now owns 86,212 shares of the biopharmaceutical company’s stock worth $615,000 after buying an additional 12,979 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its stake in shares of Amicus Therapeutics by 11.5% in the first quarter. Nationwide Fund Advisors now owns 131,945 shares of the biopharmaceutical company’s stock worth $941,000 after buying an additional 13,563 shares during the last quarter.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at 13.43 on Monday. The stock’s market capitalization is $1.92 billion. Amicus Therapeutics, Inc. has a 52 week low of $4.41 and a 52 week high of $14.05. The company’s 50 day moving average is $11.40 and its 200-day moving average is $8.12.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.02. During the same quarter in the previous year, the company posted ($0.40) EPS. On average, equities analysts predict that Amicus Therapeutics, Inc. will post ($1.44) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Legal & General Group Plc” was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/08/07/amicus-therapeutics-inc-nasdaqfold-shares-sold-by-legal-general-group-plc.html.

A number of analysts recently commented on FOLD shares. Zacks Investment Research cut shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 2nd. Robert W. Baird restated an “outperform” rating and set a $12.00 price target (up from $10.00) on shares of Amicus Therapeutics in a research note on Wednesday, May 17th. Bank of America Corporation dropped their price target on shares of Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, May 25th. Chardan Capital restated a “buy” rating and set a $12.50 price target on shares of Amicus Therapeutics in a research note on Thursday, June 1st. Finally, ValuEngine upgraded shares of Amicus Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $13.42.

In other Amicus Therapeutics news, insider Hung Do sold 29,914 shares of Amicus Therapeutics stock in a transaction that occurred on Friday, May 19th. The shares were sold at an average price of $8.00, for a total transaction of $239,312.00. Following the transaction, the insider now owns 474,438 shares of the company’s stock, valued at $3,795,504. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jay Barth sold 30,000 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $10.00, for a total transaction of $300,000.00. Following the transaction, the insider now directly owns 64,184 shares in the company, valued at approximately $641,840. The disclosure for this sale can be found here. 3.40% of the stock is owned by insiders.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.